Business Description
TuHURA Biosciences Inc
NAICS : 541714
SIC : 2833
Description
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 9.7 | |||||
| Debt-to-EBITDA | -1.54 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.34 | |||||
| 9-Day RSI | 40.22 | |||||
| 14-Day RSI | 42.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 1.54 | |||||
| Cash Ratio | 1.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -172.9 | |||||
| ROIC % | -493.74 | |||||
| ROC (Joel Greenblatt) % | -2466.36 | |||||
| ROCE % | -331.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 138.33 | |||||
| Price-to-Tangible-Book | 138.33 | |||||
| EV-to-EBIT | -18.08 | |||||
| EV-to-Forward-EBIT | -9.71 | |||||
| EV-to-EBITDA | -18.17 | |||||
| EV-to-FCF | -17.94 | |||||
| Price-to-Net-Current-Asset-Value | 223.5 | |||||
| Price-to-Net-Cash | 447 | |||||
| Earnings Yield (Greenblatt) % | -5.53 | |||||
| FCF Yield % | -6.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HURA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TuHURA Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.989 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 42.72 | ||
| 14-Day ATR ($) | 0.763347 | ||
| 20-Day SMA ($) | 5.088 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 2.92 - 7.93 | ||
| Shares Outstanding (Mil) | 42.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TuHURA Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TuHURA Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TuHURA Biosciences Inc Frequently Asked Questions
What is TuHURA Biosciences Inc(HURA)'s stock price today?
The current price of HURA is $4.50. The 52 week high of HURA is $7.93 and 52 week low is $2.92.
When is next earnings date of TuHURA Biosciences Inc(HURA)?
The next earnings date of TuHURA Biosciences Inc(HURA) is .
Does TuHURA Biosciences Inc(HURA) pay dividends? If so, how much?
TuHURA Biosciences Inc(HURA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers